amyotrophic lateral sclerosis


Biogen gets FDA approval for ALS drug Qalsody

After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral scleros


FDA advisors split on Biogen’s ALS therapy

Biogen’s chances of getting an FDA approval for its tofersen drug candidate for amyotrophic lateral sclerosis (ALS) patients who have mutations in the SOD1 gene have been